The MAGNETOM Viato.Mobile may facilitate improved access to MRI capabilities for patients with serious health conditions who lack geographic proximity to centers with advanced imaging.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the MAGNETOM Viato.Mobile, a 1.5 Tesla magnetic resonance imaging (MRI) system that is reportedly designed for easy transportation to off-site locations.
The 70 centimeter-bore scanner offers a variety of features including BioMatrix Technology and Deep Resolve image reconstruction, according to Siemens Healthineers, the manufacturer of MAGNETOM Viato.Mobile.
The company said the artificial intelligence (AI)-powered Deep Resolve technology accelerates scan times for brain scans by up to 70 percent, enhances image resolution and improves signal-to-noise ratio. Siemens Healthineers added that BioMatrix Technology prevents variation in imaging results by enabling clinicians to personalize MRI exams and compensate for different patient anatomies and physiologies.
Jane Kilkenny, the vice president of magnetic resonance at Siemens Healthineers North America, said the MAGNETOM Viato.Mobile represents an opportunity to bring the capabilities of advanced imaging to patients who don’t have geographic proximity to facilities with these imaging systems.
“The MAGNETOM Viato.Mobile demonstrates our dedication to the mobile MR market by offering the latest and greatest technologies to patients who might lack convenient access to premium diagnostic MR scanners,” noted Kilkenny. “The introduction of the MAGNETOM Viato.Mobile is yet another example of our efforts to democratize high-end imaging technology to provide greater access to care.”
New Study Finds Racial Disparities with Pre-Op Breast MRI and Positive Surgical Margin Rates
November 8th 2024In addition to a lower rate of preoperative breast MRI use, emerging research found that Black women with breast cancer who didn’t have a preoperative MRI had a higher positive surgical margin rate than White women with no preoperative MRI.
Can MRI-Based AI Enhance Pre-Op Prediction of Tumor Deposits in Patients with Rectal Cancer?
October 31st 2024For patients with rectal cancer, an emerging nomogram that combines deep learning and clinical factors had greater than 16 percent and 23 percent increases in accuracy and specificity, respectively, for pre-op prediction of tumor deposits in comparison to clinical factors alone.